Jämför metoder
Granska de valda metoderna sida vid sida; rader som skiljer sig är markerade.
| Kostnadseffektivitetsanalys inom HTA× | Hälso- och sjukvårdsteknologiutvärdering× | |
|---|---|---|
| Ämnesområde | Hälso- och sjukvårdsledning | Hälso- och sjukvårdsledning |
| Familj | Process / pipeline | Process / pipeline |
| Ursprungsår≠ | 1996 | 1980 |
| Upphovsperson≠ | Diane Meade Drummond, Michael Gold | International HTA organizations, National Institutes of Health |
| Typ≠ | Economic evaluation methodology | Structured assessment methodology |
| Ursprungskälla≠ | Gold, M. R., Siegel, J. E., Russell, L. B., & Weinstein, M. C. (Eds.). (1996). Cost-Effectiveness in Health and Medicine. Oxford University Press. ISBN: 9780195108231 | Goodman, C. S. (2004). HTA 101: Introduction to Health Technology Assessment (Version 1.0). National Library of Medicine, National Institutes of Health. link ↗ |
| Alias | CEA, Cost-Effectiveness Analysis Healthcare | HTA, Technology Assessment Healthcare |
| Närliggande | 5 | 5 |
| Sammanfattning≠ | Cost-Effectiveness Analysis (CEA) is an economic evaluation method that compares the cost and health benefits of alternative treatments to determine whether an intervention provides good value for money. Within Health Technology Assessment, CEA is the primary tool for recommending reimbursement and coverage decisions. | Health Technology Assessment (HTA) is a structured, multidisciplinary approach to evaluating the clinical, economic, and societal effects of healthcare technologies (devices, drugs, procedures, systems). HTA synthesizes evidence from clinical trials, observational studies, and economic analyses to support decision-makers in adoption and reimbursement determinations. |
| ScholarGateDatamängd ↗ |
|
|